Frost & Sullivan

MARCH 28, 2025

Download our full analysis on the top 6 growth opportunities in pharma and biotech. By 2030, the RLT market is projected to reach $13.07 Key Growth Opportunities Strategic Partnerships: Collaborations like Sanofis licensing deal with RadioMedix and Orano Med demonstrate the potential for RLT expansion into rare cancers.

Biotech 52

Biotech Biotechnology Strategic partnership Insurance 52

Frost & Sullivan

MARCH 5, 2025

Middle East: Vision 2030 is driving generative design adoption in real estate and infrastructure. Investment Outlook: Biohybrid technologies will see strong adoption in biotech, environmental science, and smart wearables. Regional Insights: APAC: South Korean startups like PAENE Biotech are pioneering mitochondrial-targeted therapies.

Biotech 52

Biotech Energy Fintech Construction 52

Frost & Sullivan

FEBRUARY 20, 2025

Middle East: Vision 2030 & Net Zero 2050 are pushing Emirates, Qatar Airways, and Etihad to lead global SAF adoption. APAC: Expected to account for 40% of global SAF demand by 2030 , with Nestes Singapore plant leading production. Leverage strategic partnerships in clean energy, biotech, and smart infrastructure.

Biotech 52

Biotech Energy Banking Government 52

Frost & Sullivan

MARCH 13, 2025

Companies must navigate regulatory challenges, leverage AI-driven innovations, and invest in strategic partnerships to stay competitive. Organizations that integrate digital health solutions, AI analytics, and robotic-assisted surgical technologies will be best positioned for success in 2030 and beyond.

Biotech 52

Biotech Utilities Strategic partnership Ecosystems 52